Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 104, Issue 4, Pages 605-612
Publisher
Springer Nature
Online
2011-02-16
DOI
10.1038/bjc.2011.17
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pyridoxine Is Not Effective to Prevent Hand-Foot Syndrome Associated With Capecitabine Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study
- (2010) Yoon-Koo Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study
- (2010) Atul Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer
- (2009) D. Y. Zang et al. ANNALS OF ONCOLOGY
- A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer
- (2009) Hyeong Su Kim et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Efficacy and Safety of S-1 Monotherapy in Patients with Advanced Biliary Tract Adenocarcinoma
- (2009) Inkeun Park et al. ONCOLOGY
- S-1 Monotherapy in Patients with Advanced Biliary Tract Cancer
- (2009) Takashi Sasaki et al. ONCOLOGY
- Association ofCYP2A6polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer
- (2009) Sun-Young Kong et al. PHARMACOGENOMICS
- Gemcitabine-based versusfluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
- (2008) Mi-Jung Kim et al. BMC CANCER
- Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial
- (2008) O Nehls et al. BRITISH JOURNAL OF CANCER
- Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer
- (2008) Y Yamada et al. BRITISH JOURNAL OF CANCER
- CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1
- (2008) Ken-ichi Fujita et al. CANCER SCIENCE
- Phase II Trial of S-1 in Combination with Oxaliplatin in Previously Untreated Patients with Recurrent or Inoperable Biliary Tract Cancer
- (2008) Sung Yong Oh et al. CHEMOTHERAPY
- The CYP2A6*4 Allele Is Determinant of S-1 Pharmacokinetics in Japanese Patients With Non-small-cell Lung Cancer
- (2008) Y Kaida et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer
- (2008) Erick Gamelin et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic Therapy for Biliary Tract Cancers
- (2008) A. F. Hezel et al. ONCOLOGIST
- The role of chemotherapy in biliary tract carcinoma
- (2008) C. Verslype et al. HPB
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search